OlympiAD trial, a phase III randomized study, investigated the efficacy of olaparib in patients with metastatic, HER2 negative BC who were carriers of deleterious germline BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA1 and breast cancer.